Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The BioEscalator’s inaugural Pitch Battle contest was held digitally at the pizza social on Friday 17 April. Eleven pitches in total were delivered by innovative companies in Oxford's medical research district, covering the broad range of drug discovery, drug development and diagnostics work being undertaken at the BioEscalator.

Congratulations to MiroBio who won the overall best pitch prize with Juliane Schwaderer, Chris Lynch and Sara de Silva delivering a slick overview of their work on harnessing the immune system’s natural control mechanisms to combat auto-immune diseases.

Other prizes were awarded to Nucleome Therapeutics for best Covid-19 response, Ochre Bio’s Jack O’Meara for best speaker, BioArchitech for best video/graphics & best joke, Theolytics for most likely future unicorn, PepGen for best explanation of technology & Ervaxx for most mentions of the BioEscalator - well done to Andrew Fadden for cramming in as many as he did!

Four of these companies have now been put through to the Pitch Finale which will be held digitally on Friday 15 May in collaboration with BIO international and generously supported by Santander Universities UK. We’re looking forward to a great event.

Find out more about the BioEscalator

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.